Latest AiCuris GmbH & Co. KG Stories
WUPPERTAL, Germany and WHITEHOUSE STATION, New Jersey, May 8, 2014 /PRNewswire/ -- AiCuris and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. The results published in the latest issue of...
- Remarkable; prodigious.
- Audacious; gutsy.
- Completely; extremely.
- Audaciously; boldly.
- Impressively great in size; enormous; extraordinary.